Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam HC1 on Insulin Sensitivity in Type 2 Diabetes
NCT00361153Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2006
- Primary completion
- Oct 2006
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Colesevelam with Placebo (2 arms). Primary endpoint: Insulin sensitivity as measured by the hyperinsulinemic-euglycemic clamp method (M-value) at 8 weeks. Started May 2006; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00361153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361153.